EBS · Emergent BioSolutions Inc.
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Equibles Research
All EBS researchGuidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | $36M | Q1 2026 call | — |
| adjusted EBITDA margin non-GAAP | 23% | Q1 2026 call | — |
| adjusted gross margin non-GAAP | 52% | Q1 2026 call | — |
| international MCM revenue percentage | 37% | Q1 2026 call | — |
| net leverage ratio non-GAAP | 2.4 | Q1 2026 call | — |
| Adjusted Net Income non-GAAP | $86.8M | Full Year 2025 | — |
| Adjusted Net Income per Diluted Share non-GAAP | $1.53 | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EBS
this stock
Emergent BioSolutions Inc.
|
$393.68M | -38.3% | -6.1% | — | 19.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$54.77B | +10.0% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.12B | +3.1% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.48B | -0.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EBS | -5.2% | -6.3% | -36.2% | -9.0% | -38.3% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -3.7% | -6.6% | -44.0% | -8.5% | -47.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.